Health Business news
QIAGEN and DiaSorin Partner to Offer Fully Automated Tuberculosis Detection With QuantiFERON-TB Gold Plus Available on LIAISON Analyzer Systems

QIAGEN and DiaSorin Partner to Offer Fully Automated Tuberculosis Detection With QuantiFERON-TB Gold Plus Available on LIAISON Analyzer Systems

SALUGGIA, Italy, HILDEN, Germany, and GERMANTOWN, Maryland, January 8, 2018 /PRNewswire/ --
QIAGEN's QuantiFERON-TB customers to gain access to fully automated workflow solution  

DiaSorin to add novel content to already broad LIAISON menu, over 7,000 systems installed  

QIAGEN announces milestone of over 40 million QuantiFERON-TB tests since launch   QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Stock Exchange: QIA) and DiaSorin (FTSE Italy Mid Cap: DIA) announced today a groundbreaking partnership that plans to add QIAGEN's QuantiFERON-TB diagnostic test to the menu of DiaSorin's LIAISON family of fully automated analyzers.

This addition will enable customers of both companies to process QuantiFERON-TB Gold Plus (QFT-Plus), the fourth-generation modern gold standard for latent tuberculosis (TB) detection, on LIAISON family platforms. Laboratories using QFT-Plus to safeguard at-risk patients by screening for latent TB infection will have access to a fully automated, flexible workflow on LIAISON family analyzers in addition to the currently available workflow solutions. More than 7,000 LIAISON systems have already placed worldwide, primarily in hospital laboratories.

QFT-Plus marks the first assay from QIAGEN's QuantiFERON portfolio that is planned to be adapted for use on the LIAISON family systems. Additional assays based on QuantiFERON technology, which offers a unique, efficient way to detect asymptomatic infections and other risks that cannot be discovered with standard diagnostic technologies, are under consideration.

QuantiFERON assays such as QFT-Plus are based on two components: (1) QuantiFERON Blood Collection Tubes, which contain key components of the test reaction that is uniquely performed in tube after blood collection; and (2) the QuantiFERON test read-out components, which are used to measure the release of interferon gamma after in-tube incubation. QFT-Plus currently runs in laboratories on standard detection equipment.

Click here for the full press release:

For additional information, please contact

For DiaSorin
Riccardo Fava
Investor Relations & Corporate Communication Senior Director
Tel: +39.0161.487988

Ines Di Terlizzi
Investor Relator
Tel: +39.0161.487567

Investor Relations
John Gilardi
Tel: +49 2103 29 11711

Public Relations
Thomas Theuringer
Tel: +49 2103 29 11826
e.mail: SOURCE Qiagen N.V.

Prev Article
Next Article

> Article Date par Qiagen N.V.

Read: 5 views

Notes :

Source : PR Newswire


Related content

: Latest news

Most read: scientific news



Follow us...

google plus Facebook twitter Newsletter



Plan du site